Phase I dose-escalation study of zelavespib in patients with relapsed myelofibrosis скачать в хорошем качестве

Phase I dose-escalation study of zelavespib in patients with relapsed myelofibrosis

Gary Schiller, MD, University of California, Los Angeles, Los Angeles, CA, outlines findings of a Phase I dose escalation study of the oral epichaperome inhibitor zelavespib in patients with relapsed myelofibrosis (MF; NCT03935555). Overall, the results demonstrated that zelavespib was well tolerated. Zelavespib has now been selected for a randomized Phase II trial which will investigate the therapeutic potential of the epichaperome inhibitor in combination with ruxolitinib in patients with relapsed MF. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.